SecBot SecBot
6-K ·Filed Jul 16, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed4mo ago SEC0001654954-26-006691
Actionable Insight • Neutral

This is a routine dividend reinvestment disclosure with no trading signal. Monitor upcoming quarterly earnings and any pipeline updates for material catalysts.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.77
T+0 close · Jul 16, 2026 · via day close
Latest settled
−11.88%
T+60 · $46.50
Vs SPY
−15.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $52.77entry
  2. T+1 · 4mo ago −1.91%α −0.92% · $51.76
  3. T+5 · 4mo ago −3.85%α −2.18% · $50.74
  4. T+20 · 3mo ago −4.40%α −8.01% · $50.45
  5. T+60 · 6w ago −11.88%α −15.59% · $46.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a routine 6-K reporting the acquisition of ADSs by multiple PDMRs (directors and officers) through dividend reinvestment following the July 9, 2026 dividend payment. Transactions occurred on July 10 and July 14, 2026, at prices between $51.67 and $52.74, with total aggregate value of approximately $82,000. This is a standard administrative disclosure with no material financial or strategic implications.

Key Facts

  • Nine PDMRs acquired ADSs via dividend reinvestment on July 10 and July 14, 2026
  • Prices ranged from $51.6696 to $52.7353 per ADS
  • Total shares acquired: approximately 2,036 ADSs
  • Total transaction value: approximately $82,000
  • Dividend paid to shareholders on July 9, 2026

Financial Impact

Approximately $82,000 in aggregate ADS acquisitions via dividend reinvestment, immaterial relative to GSK's $104B market cap

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (GSK), Batch item 10001654954-26-006691
Document: 0001654954-26-006691-index-headers.html0001654954-26-006691
Document: 0001654954-26-006691-index.html0001654954-26-006691
Document: 0001654954-26-006691.txt0001654954-26-006691
6-K Filing (GSK), Batch item 50001654954-26-006691
Document: 0001654954-26-006691-index-headers.html0001654954-26-006691
Document: 0001654954-26-006691-index.html0001654954-26-006691
Document: 0001654954-26-006691.txt0001654954-26-006691

US Market Status

Market Closed · Opens Wed (10h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 16, 2026